Prospective NIS to examine the effectiveness of TDC in patients with metastatic non-squamous NSCLC and high-risk genetic alterations - NAUTIC

Inclusion Criteria

• • Aged ≥ 18 years
• • Decision to start first-line (1L) treatment with TDC according to the current SmPCs
• • Histologically or cytologically confirmed diagnosis of NSQ mNSCLC (incl. LCNEC if considered NSCLC-like by the treating physician)
• • Treatment-naïve for metastatic disease
• • No sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) alterations
• • Molecular NGS panel as per institutional standard has been initiated (including the following genes: KRAS, STK11, KEAP1, and TP53)
• • TTF-1 expression analysis has been initiated
• • PD-L1 expression analysis has been initiated
• • Women of childbearing potential must use effective contraception during treatment with durvalumab and for at least 3 months after the last dose of durvalumab
• • Ability to understand the study concept
• • Provision of signed informed consent form in accordance with applicable local provisions